Manager × security

ARMISTICE CAPITAL, LLC REGN holdings history

Who else holds this security?

REGENERON PHARMACEUTICALS · CUSIP 75886F107 · CIK 1601086

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, ARMISTICE CAPITAL, LLC reported 89.81K REGN (shares), valued at $56.00M, or 1.55% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources
Portfolio weight and quantity history
Reported portfolio weight
1.55%
Shares
89.81K
89,809
Reported value
$56.00M
USD

Shares increased 148.60%; reported value increased 100.63%, and weight changed +0.63 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20261.55%89,809SEC filingFiled Aug 14, 2026
Q1 20260.92%36,126SEC filingFiled May 15, 2026
Q4 20251.59%84,000SEC filingFiled Feb 17, 2026
Q3 20252.21%125,206SEC filingFiled Nov 17, 2025
Q2 20251.99%100,032SEC filingFiled Aug 14, 2025
Q1 20251.93%114,073SEC filingFiled May 15, 2025
Q4 20240.46%28,045SEC filingFiled Feb 14, 2025
Q3 20240.55%20,032SEC filingFiled Nov 14, 2024
Q2 20240.33%12,064SEC filingFiled Aug 14, 2024
Q1 20240.59%22,987SEC filingFiled May 15, 2024
Q4 20231.40%60,000SEC filingFiled Feb 13, 2024
Q3 20231.83%74,998SEC filingFiled Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20231.83%74,998$61.72MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing
Filed Nov 14, 2023
Q4 20231.40%60,000$52.70MShares decreased 20.00%; reported value decreased 14.62%, and weight changed -0.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 13, 2024
Q1 20240.59%22,987$22.12MShares decreased 61.69%; reported value decreased 58.02%, and weight changed -0.81 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 15, 2024
Q2 20240.33%12,064$12.68MShares decreased 47.52%; reported value decreased 42.69%, and weight changed -0.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 14, 2024
Q3 20240.55%20,032$21.06MShares increased 66.05%; reported value increased 66.08%, and weight changed +0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 14, 2024
Q4 20240.46%28,045$19.98MShares increased 40.00%; reported value decreased 5.13%, and weight changed -0.09 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 14, 2025
Q1 20251.93%114,073$72.35MShares increased 306.75%; reported value increased 262.15%, and weight changed +1.47 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 15, 2025
Q2 20251.99%100,032$52.52MShares decreased 12.31%; reported value decreased 27.41%, and weight changed +0.06 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 14, 2025
Q3 20252.21%125,206$70.40MShares increased 25.17%; reported value increased 34.05%, and weight changed +0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Nov 17, 2025
Q4 20251.59%84,000$64.84MShares decreased 32.91%; reported value decreased 7.90%, and weight changed -0.62 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Feb 17, 2026
Q1 20260.92%36,126$27.91MShares decreased 56.99%; reported value decreased 56.95%, and weight changed -0.67 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed May 15, 2026
Q2 20261.55%89,809$56.00MShares increased 148.60%; reported value increased 100.63%, and weight changed +0.63 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing
Filed Aug 14, 2026
ARMISTICE CAPITAL, LLC · REGENERON PHARMACEUTICALS

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1601086","quarter":"2026Q2","cusip":"75886F107"}

get_institutional_manager_history
{"cik":"1601086","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.